Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats

被引:56
作者
Gomez-Guzman, Manuel [1 ]
Jimenez, Rosario [1 ]
Sanchez, Manuel [1 ]
Romero, Miguel [1 ]
O'Valle, Francisco [2 ]
Lopez-Sepulveda, Rocio [1 ]
Maria Quintela, Ana [1 ]
Galindo, Pilar [1 ]
Jose Zarzuelo, Maria [1 ]
Bailon, Elvira [1 ]
Delpon, Eva [3 ]
Perez-Vizcaino, Francisco [3 ,4 ,5 ]
Duarte, Juan [1 ]
机构
[1] Univ Granada, Dept Pharmacol, Sch Pharm, E-18071 Granada, Spain
[2] Sch Med, Dept Pathol, Granada, Spain
[3] Univ Complutense Madrid, Dept Pharmacol, Sch Med, Madrid, Spain
[4] Ciber Enfermedades Resp Ciberes, Madrid, Spain
[5] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, Madrid, Spain
关键词
(-)-Epicatechin; N-G-nitro-L-arginine methyl ester; Hypertension; Superoxide; Inflammation; FLAVANOL-RICH COCOA; PREVENTS ENDOTHELIAL DYSFUNCTION; ESTER-INDUCED HYPERTENSION; FACTOR-KAPPA-B; NADPH OXIDASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; FLAVONOID QUERCETIN; ANGIOTENSIN-II; SHORT-TERM;
D O I
10.1017/S0007114511004314
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
The present study analysed the effects of the flavanol (-)-epicatechin in rats after chronic inhibition of NO synthesis with N-G-nitro-L-arginine methyl ester (L-NAME), at doses equivalent to those achieved in the studies involving human subjects. Wistar rats were randomly divided into four groups: (1) control-vehicle, (-) L-NAME, (3) L-NAME-epicatechin 2 (L-NAME-Epi 2) and (4) L-NAME-epicatechin 10 (L-NAME-Epi 10). Rats were daily given by oral administration for 4 weeks: vehicle, (-)-epicatechin 2 or 10 mg/kg. Animals in the L-NAME groups daily received L-NAME 75 mg/100 ml in drinking-water. The evolution in systolic blood pressure and heart rate, and morphological and plasma variables, proteinuria, vascular superoxide, reactivity and protein expression at the end of the experiment were analysed. Chronic (-)-epicatechin treatment did not modify the development of hypertension and only weakly affected the endothelial dysfunction induced by L-NAME but prevented the cardiac hypertrophy, the renal parenchyma and vascular lesions and proteinuria, and blunted the prostanoid-mediated enhanced endothelium-dependent vasoconstrictor responses and the cyclo-oxygenase-2 and endothelial NO synthase (eNOS) up-regulation. Furthermore, (-)-epicatechin also increased Akt and eNOS phosphorylation and prevented the L-NAME-induced increase in systemic (plasma malonyldialdehyde and urinary 8-iso-PGF(2 alpha)) and vascular (dihydroethidium staining, NADPH oxidase activity and p22(phox) up-regulation) oxidative stress, proinflammatory status (intercellular adhesion molecule-1, IL-1 beta and TNF alpha up-regulation) and extracellular-signal-regulated kinase 1/2 phosphorylation. The present study shows for the first time that chronic oral administration of (-)-epicatechin does not improve hypertension but reduced pro-atherogenic pathways such as oxidative stress and proinflammatory status of the vascular wall induced by blockade of NO production.
引用
收藏
页码:1337 / 1348
页数:12
相关论文
共 40 条
[1]   THROMBOXANE-A2 RECEPTOR ANTAGONISTS INHIBIT ENDOTHELIUM-DEPENDENT CONTRACTIONS [J].
AUCHSCHWELK, W ;
KATUSIC, ZS ;
VANHOUTTE, PM .
HYPERTENSION, 1990, 15 (06) :699-703
[2]   Chronic NG-nitro-L-arginine methyl ester-induced hypertension -: Novel molecular adaptation to systolic load in absence of hypertrophy [J].
Bartunek, J ;
Weinberg, EO ;
Tajima, M ;
Rohrbach, S ;
Katz, SE ;
Douglas, PS ;
Lorell, BH .
CIRCULATION, 2000, 101 (04) :423-429
[3]   Isoprostanes in fetal and neonatal health and disease [J].
Belik, Jaques ;
Gonzalez-Luis, Gema E. ;
Perez-Vizcaino, Francisco ;
Villamor, Eduardo .
FREE RADICAL BIOLOGY AND MEDICINE, 2010, 48 (02) :177-188
[4]   Role of nuclear factor-kappa B in atherogenesis [J].
Brand, K ;
Page, S ;
Walli, AK ;
Neumeier, D ;
Baeuerle, PA .
EXPERIMENTAL PHYSIOLOGY, 1997, 82 (02) :297-304
[5]   Cocoa intake, blood pressure, and cardiovascular mortality - The Zutphen Elderly Study [J].
Buijsse, B ;
Feskens, EJM ;
Kok, FJ ;
Kromhout, D .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (04) :411-417
[6]   Tea and cardiovascular disease [J].
Deka, Apranta ;
Vita, Joseph A. .
PHARMACOLOGICAL RESEARCH, 2011, 64 (02) :136-145
[7]   Chocolate and prevention of cardiovascular disease: A systematic review [J].
Ding, Eric L. ;
Hutfless, Susan M. ;
Ding, Xin ;
Girotra, Saket .
NUTRITION & METABOLISM, 2006, 3 (1)
[8]   Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats [J].
Duarte, J ;
Jiménez, R ;
O'Valle, F ;
Galisteo, M ;
Pérez-Palencia, R ;
Vargas, F ;
Pérez-Vizcaíno, F ;
Zarzuelo, A ;
Tamargo, J .
JOURNAL OF HYPERTENSION, 2002, 20 (09) :1843-1854
[9]   Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats [J].
Duarte, J ;
Pérez-Palencia, R ;
Vargas, F ;
Ocete, MA ;
Pérez-Vizcaino, F ;
Zarzuelo, A ;
Tamargo, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 133 (01) :117-124
[10]   VASODILATORY EFFECTS OF FLAVONOIDS IN RAT AORTIC SMOOTH-MUSCLE - STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
DUARTE, J ;
VIZCAINO, FP ;
UTRILLA, P ;
JIMENEZ, J ;
TAMARGO, J ;
ZARZUELO, A .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1993, 24 (04) :857-862